Patent · US Active

Methods for reducing CD36 expression

US7541340B2 · kind B2 · utility

14Cited by
12References
7Claims
0Family size

Assignee

Inventors

Key dates

Filing dateSep 18, 2006
Grant dateJun 2, 2009
Priority date
Expiry dateJan 15, 2027

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61K38/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The invention provides a method of reducing CD36 expression in a cell. The method comprises contacting the cell with an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship between the minimum number of net positive charges (pm) and the total number of amino acid residues (r) wherein 3pm is the largest number that is less than or equal to r+1; and a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (pt) wherein 2a is the largest number that is less than or equal to pt−1, except that when a is 1, pt may also be 1.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.